UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 20222023
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to __________
Commission file number 001-38623
PAYSIGN, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 95-4550154 |
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |
2615 St. Rose Parkway,
Henderson, Nevada 89052
(Address of principal executive offices) (Zip code)
(702) 453-2221
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | PAYS | The NasdaqStock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated | Accelerated |
| Non-accelerated | Smaller reporting company ☒ |
| Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: shares as of August 5, 2022.4, 2023.
PAYSIGN, INC.
FORM 10-Q REPORT
INDEX
| 2 |
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
PAYSIGN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, (Unaudited) | December 31, (Audited) | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 6,527,476 | $ | 7,387,156 | ||||
| Restricted cash | 76,967,850 | 61,283,914 | ||||||
| Accounts receivable | 3,488,759 | 3,393,940 | ||||||
| Other receivables | 1,439,251 | 1,019,218 | ||||||
| Prepaid expenses and other current assets | 1,754,140 | 1,242,967 | ||||||
| Total current assets | 90,177,476 | 74,327,195 | ||||||
| Fixed assets, net | 1,410,947 | 1,642,981 | ||||||
| Intangible assets, net | 4,501,854 | 4,086,962 | ||||||
| Operating lease right-of-use asset | 3,806,793 | 3,993,655 | ||||||
| Total assets | $ | 99,897,070 | $ | 84,050,793 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 5,575,119 | $ | 5,765,478 | ||||
| Operating lease liability, current portion | 350,753 | 340,412 | ||||||
| Customer card funding | 76,967,850 | 61,283,914 | ||||||
| Total current liabilities | 82,893,722 | 67,389,804 | ||||||
| Operating lease liability, long term portion | 3,495,185 | 3,673,186 | ||||||
| Total liabilities | 86,388,907 | 71,062,990 | ||||||
| Commitments and contingencies (Note 8) | – | – | ||||||
| Stockholders' equity | ||||||||
| Preferred stock: $ par value; shares authorized; issued and outstanding | 0 | 0 | ||||||
| Common stock; $ par value; shares authorized, and issued at June 30, 2022 and December 31, 2021, respectively | 52,323 | 52,095 | ||||||
| Additional paid-in capital | 17,917,680 | 16,860,119 | ||||||
| Treasury stock at cost, shares | (150,000 | ) | (150,000 | ) | ||||
| Accumulated deficit | (4,311,840 | ) | (3,774,411 | ) | ||||
| Total stockholders' equity | 13,508,163 | 12,987,803 | ||||||
| Total liabilities and stockholders' equity | $ | 99,897,070 | $ | 84,050,793 | ||||
June 30, (Unaudited) | December 31, (Audited) | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 7,670,677 | $ | 9,708,238 | ||||
| Restricted cash | 78,365,845 | 80,189,113 | ||||||
| Accounts receivable, net | 7,749,451 | 4,680,991 | ||||||
| Other receivables | 1,238,020 | 1,439,251 | ||||||
| Prepaid expenses and other current assets | 2,290,792 | 1,699,808 | ||||||
| Total current assets | 97,314,785 | 97,717,401 | ||||||
| Fixed assets, net | 1,124,242 | 1,255,292 | ||||||
| Intangible assets, net | 6,998,727 | 5,656,722 | ||||||
| Operating lease right-of-use asset | 3,417,635 | 3,614,838 | ||||||
| Total assets | $ | 108,855,389 | $ | 108,244,253 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 10,484,747 | $ | 8,088,660 | ||||
| Operating lease liability, current portion | 372,387 | 361,408 | ||||||
| Customer card funding | 78,365,845 | 80,189,113 | ||||||
| Total current liabilities | 89,222,979 | 88,639,181 | ||||||
| Operating lease liability, long term portion | 3,122,798 | 3,311,777 | ||||||
| Total liabilities | 92,345,777 | 91,950,958 | ||||||
| Commitments and contingencies (Note 8) | – | – | ||||||
| Stockholders' equity | ||||||||
| Preferred stock, $ par value; shares authorized; issued and outstanding | – | – | ||||||
| Common stock, $ par value; shares authorized; and issued at June 30, 2023 and December 31, 2022, respectively | 52,842 | 52,650 | ||||||
| Additional paid-in capital | 20,595,359 | 19,137,281 | ||||||
| Treasury stock, at cost; and shares, respectively | (1,127,667 | ) | (150,000 | ) | ||||
| Accumulated deficit | (3,010,922 | ) | (2,746,636 | ) | ||||
| Total stockholders' equity | 16,509,612 | 16,293,295 | ||||||
| Total liabilities and stockholders' equity | $ | 108,855,389 | $ | 108,244,253 | ||||
See accompanying notes to unaudited condensed consolidated financial statements.
| 3 |
PAYSIGN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | ||||||||||||||||
| Plasma industry | $ | 7,806,201 | $ | 5,947,313 | $ | 15,200,565 | $ | 11,330,464 | ||||||||
| Pharma industry | 773,311 | 641,037 | 1,579,879 | 1,523,867 | ||||||||||||
| Other | 19,264 | 62,940 | 38,971 | 76,387 | ||||||||||||
| Total revenues | 8,598,776 | 6,651,290 | 16,819,415 | 12,930,718 | ||||||||||||
| Cost of revenues | 3,900,965 | 3,498,723 | 7,123,355 | 6,946,345 | ||||||||||||
| Gross profit | 4,697,811 | 3,152,567 | 9,696,060 | 5,984,373 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 4,255,976 | 3,474,562 | 8,896,888 | 7,339,548 | ||||||||||||
| Depreciation and amortization | 713,180 | 614,182 | 1,392,351 | 1,210,030 | ||||||||||||
| Total operating expenses | 4,969,156 | 4,088,744 | 10,289,239 | 8,549,578 | ||||||||||||
| Loss from operations | (271,345 | ) | (936,177 | ) | (593,179 | ) | (2,565,205 | ) | ||||||||
| Other income | ||||||||||||||||
| Interest income, net | 70,227 | 5,010 | 84,563 | 12,111 | ||||||||||||
| Loss before income tax provision | (201,118 | ) | (931,167 | ) | (508,616 | ) | (2,553,094 | ) | ||||||||
| Income tax provision | 26,916 | 800 | 28,813 | 2,400 | ||||||||||||
| Net loss | $ | (228,034 | ) | $ | (931,967 | ) | $ | (537,429 | ) | $ | (2,555,494 | ) | ||||
| Net loss per share | ||||||||||||||||
| Basic | $ | (0.00 | ) | $ | (0.02 | ) | $ | (0.01 | ) | $ | (0.05 | ) | ||||
| Diluted | $ | (0.00 | ) | $ | (0.02 | ) | $ | (0.01 | ) | $ | (0.05 | ) | ||||
| Weighted average common shares | ||||||||||||||||
| Basic | 51,993,031 | 50,748,437 | 51,906,335 | 50,551,299 | ||||||||||||
| Diluted | 51,993,031 | 50,748,437 | 51,906,335 | 50,551,299 | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenues | ||||||||||||||||
| Plasma industry | $ | 10,014,461 | $ | 7,806,201 | $ | 19,374,528 | $ | 15,200,565 | ||||||||
| Pharma industry | 729,236 | 773,311 | 1,318,798 | 1,579,879 | ||||||||||||
| Other | 297,354 | 19,264 | 491,015 | 38,971 | ||||||||||||
| Total revenues | 11,041,051 | 8,598,776 | 21,184,341 | 16,819,415 | ||||||||||||
| Cost of revenues | 5,425,311 | 3,900,965 | 10,520,932 | 7,123,355 | ||||||||||||
| Gross profit | 5,615,740 | 4,697,811 | 10,663,409 | 9,696,060 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 5,304,625 | 4,255,976 | 10,250,075 | 8,896,888 | ||||||||||||
| Depreciation and amortization | 958,001 | 713,180 | 1,803,017 | 1,392,351 | ||||||||||||
| Total operating expenses | 6,262,626 | 4,969,156 | 12,053,092 | 10,289,239 | ||||||||||||
| Loss from operations | (646,886 | ) | (271,345 | ) | (1,389,683 | ) | (593,179 | ) | ||||||||
| Other income | ||||||||||||||||
| Interest income, net | 600,867 | 70,227 | 1,185,064 | 84,563 | ||||||||||||
| Loss before income tax provision | (46,019 | ) | (201,118 | ) | (204,619 | ) | (508,616 | ) | ||||||||
| Income tax provision | 58,137 | 26,916 | 59,667 | 28,813 | ||||||||||||
| Net loss | $ | (104,156 | ) | $ | (228,034 | ) | $ | (264,286 | ) | $ | (537,429 | ) | ||||
| Net loss per share | ||||||||||||||||
| Basic | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.01 | ) | ||||
| Diluted | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.01 | ) | ||||
| Weighted average common shares | ||||||||||||||||
| Basic | 52,259,002 | 51,993,031 | 52,330,829 | 51,906,335 | ||||||||||||
| Diluted | 52,259,002 | 51,993,031 | 52,330,829 | 51,906,335 | ||||||||||||
See accompanying notes to unaudited condensed consolidated financial statements.
| 4 |
PAYSIGN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(UNAUDITED)
| Common Stock | Additional Paid-in | Treasury Stock | Accumulated | Total Stockholders’ | Common Stock | Additional Paid-in | Treasury Stock | Accumulated | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Capital | Amount | Deficit | Equity | Shares | Amount | Capital | Shares | Amount | Deficit | Equity | ||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2021 | 52,095,382 | $ | 52,095 | $ | 16,860,119 | $ | (150,000 | ) | $ | (3,774,411 | ) | $ | 12,987,803 | |||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2022 | 52,650,382 | $ | 52,650 | $ | 19,137,281 | (303,450 | ) | $ | (150,000 | ) | $ | (2,746,636 | ) | $ | 16,293,295 | |||||||||||||||||||||||||||||||||||||
| Stock issued upon vesting of restricted stock | 123,000 | 123 | (123 | ) | – | – | – | 118,000 | 118 | (118 | ) | – | – | – | – | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation | – | – | 569,502 | – | – | 569,502 | – | – | 618,244 | – | – | – | 618,244 | |||||||||||||||||||||||||||||||||||||||
| Repurchase of common stock | – | – | – | (200,000 | ) | (666,018 | ) | – | (666,018 | ) | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | (309,395 | ) | (309,395 | ) | – | – | – | – | – | (160,130 | ) | (160,130 | ) | |||||||||||||||||||||||||||||||||||
| Balance, March 31, 2022 | 52,218,382 | $ | 52,218 | $ | 17,429,498 | $ | (150,000 | ) | $ | (4,083,806 | ) | $ | 13,247,910 | |||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2023 | 52,768,382 | 52,768 | 19,755,407 | (503,450 | ) | (816,018 | ) | (2,906,766 | ) | 16,085,391 | ||||||||||||||||||||||||||||||||||||||||||
| Stock issued upon vesting of restricted stock | 105,000 | 105 | (105 | ) | – | – | – | 70,000 | 70 | (70 | ) | – | – | – | – | |||||||||||||||||||||||||||||||||||||
| Exercise of stock options | 4,000 | 4 | 9,596 | – | – | – | 9,600 | |||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | – | – | 488,287 | – | – | – | – | – | 830,426 | – | – | – | 830,426 | |||||||||||||||||||||||||||||||||||||||
| Repurchase of common stock | – | – | – | (119,558 | ) | (311,649 | ) | – | (311,649 | ) | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | $ | (228,034 | ) | $ | (228,034 | ) | – | – | – | – | – | (104,156 | ) | (104,156 | ) | |||||||||||||||||||||||||||||||||
| Balance, June 30, 2022 | 52,323,382 | $ | 52,323 | $ | 17,917,680 | $ | (150,000 | ) | $ | (4,311,840 | ) | $ | 13,508,163 | |||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2023 | 52,842,382 | $ | 52,842 | $ | 20,595,359 | (623,008 | ) | $ | (1,127,667 | ) | $ | (3,010,922 | ) | $ | 16,509,612 | |||||||||||||||||||||||||||||||||||||
| Common Stock | Additional Paid-in | Treasury Stock | Accumulated | Total Stockholders’ | ||||||||||||||||||||
| Shares | Amount | Capital | Amount | Deficit | Equity | |||||||||||||||||||
| Balance, December 31, 2020 | 50,251,607 | $ | 50,252 | $ | 14,388,890 | $ | (150,000 | ) | $ | (1,053,077 | ) | $ | 13,236,065 | |||||||||||
| Stock issued upon vesting of restricted stock | 466,689 | 467 | (467 | ) | – | – | – | |||||||||||||||||
| Exercise of stock options | 32,586 | 32 | 110,434 | – | – | 110,466 | ||||||||||||||||||
| Stock-based compensation | – | – | 636,214 | – | – | 636,214 | ||||||||||||||||||
| Net loss | – | – | – | – | (1,623,527 | ) | (1,623,527 | ) | ||||||||||||||||
| Balance, March 31, 2021 | 50,750,882 | 50,751 | 15,135,071 | (150,000 | ) | (2,676,604 | ) | 12,359,218 | ||||||||||||||||
| Stock issued upon vesting of restricted stock | 390,000 | 390 | (390 | ) | – | – | – | |||||||||||||||||
| Exercise of stock options | 2,500 | 2 | 9,673 | – | – | 9,675 | ||||||||||||||||||
| Stock-based compensation | – | – | 540,921 | – | – | 540,921 | ||||||||||||||||||
| Net loss | – | – | – | – | (931,967 | ) | (931,967 | ) | ||||||||||||||||
| Balance, June 30, 2021 | 51,143,382 | $ | 51,143 | $ | 15,685,275 | $ | (150,000 | ) | $ | (3,608,571 | ) | $ | 11,977,847 | |||||||||||
| Common Stock | Additional Paid-in | Treasury Stock | Accumulated | Total Stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Capital | Shares | Amount | Deficit | Equity | ||||||||||||||||||||||
| Balance, December 31, 2021 | 52,095,382 | $ | 52,095 | $ | 16,860,119 | (303,450 | ) | $ | (150,000 | ) | $ | (3,774,411 | ) | $ | 12,987,803 | |||||||||||||
| Stock issued upon vesting of restricted stock | 123,000 | 123 | (123 | ) | – | – | – | – | ||||||||||||||||||||
| Stock-based compensation | – | – | 569,502 | – | – | – | 569,502 | |||||||||||||||||||||
| Net loss | – | – | – | – | – | (309,395 | ) | (309,395 | ) | |||||||||||||||||||
| Balance, March 31, 2022 | 52,218,382 | 52,218 | 17,429,498 | (303,450 | ) | (150,000 | ) | (4,083,806 | ) | 13,247,910 | ||||||||||||||||||
| Stock issued upon vesting of restricted stock | 105,000 | 105 | (105 | ) | – | – | – | – | ||||||||||||||||||||
| Stock-based compensation | – | – | 488,287 | – | – | – | 488,287 | |||||||||||||||||||||
| Net loss | – | – | – | – | – | (228,034 | ) | (228,034 | ) | |||||||||||||||||||
| Balance, June 30, 2022 | 52,323,382 | $ | 52,323 | $ | 17,917,680 | (303,450 | ) | $ | (150,000 | ) | $ | (4,311,840 | ) | $ | 13,508,163 | |||||||||||||
See accompanying notes to unaudited condensed consolidated financial statements.
| 5 |
PAYSIGN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (537,429 | ) | $ | (2,555,494 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Stock-based compensation expense | 1,057,789 | 1,210,030 | ||||||
| Depreciation and amortization | 1,392,351 | 1,177,135 | ||||||
| Noncash lease expense | 186,862 | 211,407 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (94,819 | ) | (293,095 | ) | ||||
| Other receivable | (420,033 | ) | 0 | |||||
| Prepaid expenses and other current assets | (511,173 | ) | (366,502 | ) | ||||
| Accounts payable and accrued liabilities | (190,359 | ) | 701,581 | |||||
| Operating lease liability | (167,660 | ) | (157,920 | ) | ||||
| Customer card funding | 15,683,936 | 17,654,611 | ||||||
| Net cash provided by operating activities | 16,399,465 | 17,581,753 | ||||||
| Cash flows from investing activities: | ||||||||
| Purchase of fixed assets | (38,188 | ) | (173,479 | ) | ||||
| Capitalization of internally developed software | (1,537,021 | ) | (1,048,364 | ) | ||||
| Purchase of intangible assets | 0 | (39,713 | ) | |||||
| Net cash used in investing activities | (1,575,209 | ) | (1,261,556 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from exercise of stock options | 0 | 120,141 | ||||||
| Net cash provided by financing activities | 0 | 120,141 | ||||||
| Net change in cash and restricted cash | 14,824,256 | 16,440,338 | ||||||
| Cash and restricted cash, beginning of period | 68,671,070 | 55,930,404 | ||||||
| Cash and restricted cash, end of period | $ | 83,495,326 | $ | 72,370,742 | ||||
| Cash and restricted cash reconciliation: | ||||||||
| Cash | 6,527,476 | 6,615,180 | ||||||
| Restricted cash | 76,967,850 | 65,755,562 | ||||||
| Total cash and restricted cash | $ | 83,495,326 | $ | 72,370,742 | ||||
| Supplemental cash flow information: | ||||||||
| Non-cash financing activities | ||||||||
| Cash paid for taxes | $ | 8,700 | $ | 2,400 | ||||
| Interest paid | $ | 821 | $ | 2,173 | ||||
| Six Months Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (264,286 | ) | $ | (537,429 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Gain on disposal assets | (4,862 | ) | – | |||||
| Stock-based compensation expense | 1,448,670 | 1,057,789 | ||||||
| Depreciation and amortization | 1,803,017 | 1,392,351 | ||||||
| Noncash lease expense | 197,203 | 186,862 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (3,068,460 | ) | (94,819 | ) | ||||
| Other receivable | 201,231 | (420,033 | ) | |||||
| Prepaid expenses and other current assets | (590,984 | ) | (511,173 | ) | ||||
| Accounts payable and accrued liabilities | 2,431,087 | (190,359 | ) | |||||
| Operating lease liability | (178,000 | ) | (167,660 | ) | ||||
| Customer card funding | (1,823,268 | ) | 15,683,936 | |||||
| Net cash provided by operating activities | 151,348 | 16,399,465 | ||||||
| Cash flows from investing activities: | ||||||||
| Purchase of fixed assets | (84,911 | ) | (38,188 | ) | ||||
| Capitalization of internally developed software | (2,959,199 | ) | (1,537,021 | ) | ||||
| Net cash used in investing activities | (3,044,110 | ) | (1,575,209 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from exercise of options | 9,600 | – | ||||||
| Repurchase of common stock | (977,667 | ) | – | |||||
| Net cash used in financing activities | (968,067 | ) | – | |||||
| Net change in cash and restricted cash | (3,860,829 | ) | 14,824,256 | |||||
| Cash and restricted cash, beginning of period | 89,897,351 | 68,671,070 | ||||||
| Cash and restricted cash, end of period | $ | 86,036,522 | $ | 83,495,326 | ||||
| Cash and restricted cash reconciliation: | ||||||||
| Cash | $ | 7,670,677 | $ | 6,527,476 | ||||
| Restricted cash | 78,365,845 | 76,967,850 | ||||||
| Total cash and restricted cash | $ | 86,036,522 | $ | 83,495,326 | ||||
| Supplemental cash flow information: | ||||||||
| Non-cash financing activities | ||||||||
| Cash paid for taxes | $ | 159,510 | $ | 8,700 | ||||
| Interest paid | $ | – | $ | 821 | ||||
See accompanying notes to unaudited condensed consolidated financial statements.
| 6 |
PAYSIGN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT POLICIES
The foregoing unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by GAAP for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2021.2022. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.
The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company’s financial position and results of operations.
Operating results for the three and six months ended June 30, 20222023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.2023.
Impact of COVID-19 Pandemic
The coronavirus (“COVID-19”) pandemic, which started in late 2019 and reached the United States in early 2020, continues to significantly impact the economy of the United States and the rest of the world. While the direct disruption appears to have significantly mitigated due to the availability of vaccines and other factors, the ultimate duration and severity of the pandemic remain uncertain, particularly given the development of new variants that continue to spread, and the economic repercussions are still manifesting themselves. The COVID-19 outbreak caused plasma center closures, and the stimulus packages signed into law during 2020 and 2021 reduced the incentive for individuals to donate plasma for supplementary income. Additionally, labor shortages at plasma donation centers and restrictions preventing Mexican nationals with tourist visas from being compensated for donating plasma, have further impacted donations. Those developments have had, and are expected to continue to have, an adverse impact on the Company’s results of operations. Offsetting those headwinds, inflationary pressures for food, gasoline, and other products and services appear to be driving individuals back into the plasma donation centers based upon the increase we experienced in the number of loads per average donation center in the second quarter of 2022 versus the first quarter of 2022. While we remain cautiously optimistic and have seen improvements in our operating results on an aggregated basis, we cannot foresee how long it may take the Company to attain pre-pandemic operating levels on a per plasma donation center basis. Given the uncertainty around the extent and timing of the potential future spread or mitigation of COVID-19 and variants and around the imposition or relaxation of protective measures, management cannot at this time estimate with reasonable accuracy COVID-19’s further impact on the Company’s results of operations, cash flows or financial condition.
Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) signed into law in 2020 and the subsequent extension of the CARES Act through September 30, 2021, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company has elected an accounting policy to recognize the government assistance when it is probable that the Company is eligible to receive the assistance and present the credit be as a reduction of the related expense. During the quarter ended June 30, 2022 the Company filed for a refund and recorded $459,755 related to the employee retention credit. As of June 30, 2022 and December 31, 2021, the Company has $1,296,488 and $876,456, respectively in other receivables on the condensed consolidated balance sheet related to refunds.
About Paysign, IncInc..
Paysign, Inc. (the “Company,” “Paysign,” “we” or “our”) was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. Paysign.Paysign is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing designed for businesses, consumers and government institutions. Headquartered in Nevada, the company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality and retail.
Principles of Consolidation – The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.
Reclassifications – In our cash flows statement, certain accounts related to the lease accounting captions in the prior periods have been reclassified to conform to the current period financial statement presentations.
Use of Estimates – The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and (iii) the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents – The Company considers all highly liquid investments purchased with an original maturity of sixthree months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows. The Company had 0no cash equivalents at June 30, 20222023 and December 31, 2021.2022.
Restricted Cash – At June 30, 20222023 and December 31, 2021,2022, restricted cash consisted of funds held specifically for our card product and pharma programs that are contractually restricted to use. The Company includes changes in restricted cash balances with cash and cash equivalents when reconciling the beginning and ending total amounts in our condensed consolidated statements of cash flows.
| 7 |
Concentrations of Credit Risk – Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash. PaysignThe Company maintains its cash and cash equivalents and restricted cash in various bank accounts that,primarily with one financial institution in the United States which at times, may exceed federally insured limits. PaysignIf this financial institution were to be placed into receivership, we may be unable to access the cash we have on deposit. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected. The Company has not experienced, nor does it anticipate, any losses with respect to such accounts. AtAs of June 30, 20222023 and December 31, 2021,2022, the Company had approximately $37,047,58638,206,698 and $31,828,82643,516,155 in excess of federally insured bank account limits, respectively.
TheAs of June 30, 2023, the Company also has a concentration of accounts receivable risk, at June 30, 2022 as two Pharmapharma program customers associated with our Pharma copaypharma patient affordability programs each individually represent 5135% and 1114% of our accounts receivable balance. Two Pharmapharma program customers each individually represented 5235% and 1724% of our accounts receivable balance aton December 31, 2021.2022.
Fixed Assets – Fixed assets are stated at cost less accumulated depreciation. Depreciation is principally recorded onusing the straight-line method over the estimated useful life of the asset, which is generally 3 to 10 years. The cost of repairs and maintenance is charged to expense as incurred. Leasehold improvements are capitalized and depreciated over the shorter of the remaining lease term or the estimated useful life of the improvements. Expenditures for property betterments and renewals are capitalized. Upon sale or other disposition of a depreciable asset, cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in other income (expense).
The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of fixed assets or whether the remaining balance of fixed assets should be evaluated for possible impairment. The Company uses an estimate of the related undiscounted cash flows over the remaining life of the fixed assets in measuring their recoverability.
Intangible Assets – For intangible assets, the Company recognizes an impairment loss if the carrying amount of the intangible asset is not recoverable and exceeds its fair value. The carrying amount of the intangible asset is considered not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use of the asset.
Intangible assets with a finite life are amortized on a straight-line basis over its estimated useful life, which is generally 3 to 15 years.
Internally Developed Software Costs - Computer software development costs are expensed as incurred, except for internal use software or website development costs that qualify for capitalization as described below, and include compensation and related expenses, costs of hardware and software, and costs incurred in developing features and functionality.
For computer software developed or obtained for internal use, costs that are incurred in the preliminary project and post implementation stages of software development are expensed as incurred. Costs incurred during the application and development stage are capitalized. Capitalized costs are amortized using the straight-line method over a 3three year estimated useful life, beginning in the period in which the software is available for use.
Contract Assets- Incremental costs to obtain or fulfill a contract with a customer are capitalized. The Company determines the costs that are incremental by confirming the costs (i) are directly related to a customer’s contract, (ii) generate or enhance resources to fulfill contract performance obligations in the future, and (iii) are recoverable. Amortization is on a straight-line basis generally over three to five years, beginning when goods and services are transferred to the customer or group of customers.
Customer Card Funding – AtAs of June 30, 20222023 and December 31, 2021,2022, customer card funding represents funds loaded or available to be loaded on cards for our prepaidthe Company’s card product programs.
| 8 |
Revenue and Expense Recognition – In determining when and how revenue is recognized from contracts with customers, the Company performs the following five-step analysis: (i) identification of contracts with customers;customers, (ii) determination of performance obligations;obligations, (iii) measurement of the transaction price;price, (iv) allocation of the transaction price to the performance obligations;obligations, and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.
The Company generates revenues from Plasmaplasma card programs through fees generated from cardholder fees and interchange fees. Revenues from Pharmapharma card programs are generated through card program management fees, transaction claims processing fees, interchange fees, and settlement income.
Plasma and Pharmapharma card program revenues include both fixed and variable components. Cardholder fees represent an obligation to the cardholder based on a per transaction basis and are recognized at a point in time when the performance obligation is fulfilled. Card program management fees and transaction claims processing fees include an obligation to our card program sponsors and are generally recognized when earned on a monthly basis and are typically due within 30 days pursuant to the contract terms which are generally multi-year contracts. The Company uses the output method to recognize card program management fee revenue at the amount of consideration to which an entity has a right to invoice. The performance obligation is satisfied when the services are transferred to the customer which the Company determined to be monthly, as the customer simultaneously receives and consumes the benefit from the Company’s performance. Interchange fees are earned when customer-issued cards are processed through card payment networks as the nature of our promise to the customer is that we stand ready to process transactions at the customer’s requests on a daily basis over the contract term. Since the timing and quantity of transactions to be processed by us are not determinable, we view interchange fees to comprise an obligation to stand ready to process as many transactions as the customer requests. Accordingly, the promise to stand ready is accounted for as a single series performance obligation. The Company uses the right to invoice practical expedient and recognizes interchange fee revenue concurrent with the processing of card transactions. Interchange fees are settled in accordance with the card payment network terms and conditions, which is typically within a few days.
The Company utilizes the remote method of revenue recognition for settlement income whereby the unspent balances will be recognized as revenue at the expiration of the cards and the respective program. This has historically been associated with the pharma prepaid business which ended in 2022. The Company records all revenue on a gross basis since it is the primary obligor and establishes the price in the contract arrangement with its customers. The Company is currently under no obligation for refundingto refund any fees, and the Company does not currently have any obligations for disputed claim settlements. Given the nature of the Company’s services and contracts, generally it has no contract assets.
Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, and sales and commission expense.
Operating leasesLeases – The Company determines if a contract is or contains a leasing element at contract inception or the date in which a modification of an existing contract occurs. In order for a contract to be considered a lease, the contract must transfer the right to control the use of an identified asset for a period of time in exchange for consideration. Control is determined to have occurred if the lessee has the right to (i) obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use and (ii) direct the use of the identified asset.
In determining the present value of lease payments at lease commencement date, the Company utilizes its incremental borrowing rate based on the information available, unless the rate implicit in the lease is readily determinable. The liability for operating leases is based on the present value of future lease payments. Operating lease expenses are recorded as rent expense, which is included within selling, general and administrative expenses within the consolidated statements of operations and presented as operating cash outflows within the consolidated statements of cash flows.
| 9 |
Leases with an initial term of 12 months or less are not recorded on the balance sheet, with lease expenseexpenses for these leases recognized on a straight-line basis over the lease term.
Stock-Based Compensation – The Company recognizes compensation expense for all restricted stock awards and stock options. The fair value of restricted stock awards is measured using the grant date trading price of our stock. The fair value of stock options is estimated at the grant date using the Black-Scholes option-pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. We have elected to recognize compensation expense for all options with graded vesting on a straight-line basis over the vesting period of the entire option. The determination of fair value using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility and the risk-free interest rate.
Recently IssuedAdopted Accounting Pronouncements – In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments–Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides updated guidance on how an entity should measure credit losses on all financial instruments carried at amortized cost (including loans held for investment and held-to-maturity debt securities, as well as trade receivables, reinsurance recoverables, and receivables that relate to repurchase agreements and securities lending agreements), a lessor’s net investments in leases, and off-balance sheet credit exposures not accounted for as insurance or as derivatives, including loan commitments, standby letters of credit, and financial guarantees. Subsequently, in November 2018 the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments–Credit Losses, which clarified that receivables arising from operating leases are not within the scope of Subtopic 326-20, but instead should be accounted for in accordance with Topic 842, Leases. In March 2022 the FASB issued ASU No. 2022-02, Financial Instruments—Credit Losses: Troubled Debt Restructurings and Vintage Disclosures which clarified accounting treatment required for trouble debt restructurings by creditors and enhanced disclosures for write-offs. The new standard and related amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently evaluating theadopted this guidance; however, there was no material impact of adopting this guidance on our Financial Statements; however, we do not expect it to have a material impactadoption on the Company’s consolidated financial statements.position, results of operations, or cash flows.
In October 2021,2. FIXED ASSETS, NET
Fixed assets consist of the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606). This guidance is effectivefollowing:
| Schedule of fixed assets | ||||||||
| June 30, 2023 | December 31, 2022 | |||||||
| Equipment | $ | 2,241,935 | $ | 2,161,424 | ||||
| Software | 331,852 | 327,452 | ||||||
| Furniture and fixtures | 757,662 | 757,661 | ||||||
| Website costs | 69,881 | 69,881 | ||||||
| Leasehold improvements | 229,772 | 229,772 | ||||||
| 3,631,102 | 3,546,190 | |||||||
| Less: accumulated depreciation | 2,506,860 | 2,290,898 | ||||||
| Fixed assets, net | $ | 1,124,242 | $ | 1,255,292 | ||||
Depreciation expense for the Company beginning on January 1,three months ended June 30, 2023 and is not expected to have a material impact on2022 was $107,615 and $134,253, respectively. Depreciation expense for the Company’s consolidated financial statements.six months ended June 30, 2023 and 2022 was $215,961 and $270,222, respectively.
| 10 |
2. FIXED ASSETS, NET
Fixed assets consist of the following:
| Schedule of fixed assets | ||||||||
| June 30, 2022 | December 31, 2021 | |||||||
| Equipment | $ | 2,098,522 | $ | 2,067,834 | ||||
| Software | 323,355 | 315,855 | ||||||
| Furniture and fixtures | 757,662 | 757,662 | ||||||
| Website costs | 69,881 | 69,881 | ||||||
| Leasehold improvements | 229,772 | 229,772 | ||||||
| 3,479,192 | 3,441,004 | |||||||
| Less: accumulated depreciation | 2,068,245 | 1,798,023 | ||||||
| Fixed assets, net | $ | 1,410,947 | $ | 1,642,981 | ||||
Depreciation expense for the three months ended June 30, 2022 and 2021 was $134,253 and $133,174, respectively. Depreciation expense for the six months ended June 30, 2022 and 2021 was $270,222 and $265,125, respectively.
3. INTANGIBLE ASSETS, NET
Intangible assets consist of the following:
| Schedule of intangible assets | ||||||||||||||||
| June 30, 2022 | December 31, 2021 | June 30, 2023 | December 31, 2022 | |||||||||||||
| Patents and trademarks | $ | 38,186 | $ | 38,186 | $ | 38,186 | $ | 38,186 | ||||||||
| Platform | 11,391,538 | 9,853,823 | 16,571,814 | 13,656,014 | ||||||||||||
| Customer lists and contracts | 1,177,200 | 1,177,200 | 1,177,200 | 1,177,200 | ||||||||||||
| Licenses | 209,282 | 209,282 | 209,282 | 209,282 | ||||||||||||
| Hosting implementation | 43,400 | – | ||||||||||||||
| Contract assets | 150,000 | 185,000 | ||||||||||||||
| 12,816,206 | 11,278,491 | 18,189,882 | 15,265,682 | |||||||||||||
| Less: accumulated amortization | 8,314,352 | 7,191,529 | 11,191,155 | 9,608,960 | ||||||||||||
| Intangible assets, net | $ | 4,501,854 | $ | 4,086,962 | $ | 6,998,727 | $ | 5,656,722 | ||||||||
Intangible assets are amortized over their useful lives ranging from periods of 3 to 15 years. Amortization expense for the three months ended June 30, 20222023 and 20212022 was $578,927 850,386and $481,008578,927, respectively. Amortization expense for the six months ended June 30, 20222023 and 20212022 was $1,122,129 1,587,056and $944,9051,122,129, respectively.
4. LEASE
The Company entered into an operating lease for office space which became effective in June 2020. The lease term is 10 years from the effective date and allows for two optional extensions of five years each. The two optional extensions are not recognized as part of the right-of-use asset or lease liability since it is not reasonably certain that the Company will extend this lease. As of June 30, 2022,2023, the remaining lease term was 7.96.91 years and the discount rate was 6%.
Operating lease cost included in selling, general and administrative expenses was $184,329196,214 and $379,435 for the three and six months ended June 30, 2023, respectively. Operating lease cost included in selling, general and administrative expenses was $184,329 and $367,550 for the three and six months ended June 30, 2022, respectively. Operating
The following is the lease cost included in selling, general and administrative expenses was $209,056 and $424,200 for the three and six months endedmaturity analysis of our operating lease as of June 30, 2021, respectively.2023:
Year ending December 31,
| Schedule of operating lease maturities | ||||
| 2023 (excluding the six months ended June 30, 2023) | $ | 285,984 | ||
| 2024 | 571,968 | |||
| 2025 | 612,006 | |||
| 2026 | 640,604 | |||
| 2027 | 640,604 | |||
| Thereafter | 1,548,127 | |||
| Total lease payments | 4,299,293 | |||
| Less: Imputed interest | (804,108 | ) | ||
| Present value of future lease payments | 3,495,185 | |||
| Less: current portion of lease liability | (372,387 | ) | ||
| Long-term portion of lease liability | $ | 3,122,798 |
| 11 |
The following is the lease maturity analysis of our operating lease as of June 30, 2022:
Year ending December 31,
| Schedule of operating lease liabilities | ||||
| 2022 (excluding the six months ended June 30, 2022) | $ | 285,984 | ||
| 2023 | 571,968 | |||
| 2024 | 571,968 | |||
| 2025 | 612,006 | |||
| 2026 | 640,604 | |||
| Thereafter | 2,188,731 | |||
| Total lease payments | 4,871,261 | |||
| Less: Imputed interest | (1,025,323 | ) | ||
| Present value of future lease payments | 3,845,938 | |||
| Less: current portion of lease liability | (350,753 | ) | ||
| Long-term portion of lease liability | $ | 3,495,185 | ||
5. CUSTOMER CARD FUNDING LIABILITY
The Company issues prepaid cards with various provisions for cardholder fees or expiration. Revenue generated from cardholder transactions and interchange fees are recognized when the Company’s performance obligation is fulfilled. Unspent balances left on Pharmapharma cards are recognized as settlement income at the expiration of the cards and the program. Contract liabilities related to prepaid cards represent funds on card and client funds held to be loaded to card before the amounts are ultimately spent by the cardholders or recognized as revenue by the Company. Contract liabilities related to prepaid cards are reported as Customer card funding liability on the condensed consolidated balance sheet.
The opening and closing balances of the Company's contract liabilities are as follows:
| Schedule of contract liabilities | ||||||||||||||||
Six Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2023 | 2022 | |||||||||||||
| Beginning balance | $ | 61,283,914 | $ | 48,100,951 | $ | 80,189,113 | $ | 61,283,914 | ||||||||
| Increase, net | 15,683,936 | 17,654,611 | ||||||||||||||
| Decrease, net | (1,823,268 | ) | 15,683,936 | |||||||||||||
| Ending balance | $ | 76,967,850 | $ | 65,755,562 | $ | 78,365,845 | $ | 76,967,850 | ||||||||
The amount of revenue recognized during the six months ended June 30, 20222023 and 20212022 that was included in the opening contract liability for prepaid cards was $1,485,0052,020,224 and $1,023,0551,485,005, respectively.
6. COMMON STOCK
At June 30, 2022,2023, the Company's authorized capital stock was shares of common stock, par value $ per share, and shares of preferred stock, par value $ per share. On that date, the Company had shares of common stock issued and shares of common stock outstanding, and shares of preferred stock outstanding.
Stock-based compensation expense related to Company grants for the three and six months ended June 30, 20222023 was $and $, respectively. Stock-based compensation expense for the three and six months ended June 30, 20212022 was $ and $, respectively.
2023 Transactions: During the three and six months ended June 30, 2023 the Company issued and shares of common stock for vested stock awards and the exercise of stock options. The Company received proceeds of $9,600 for the exercise of stock options.
During the three and six months ended June 30, 2023 the Company repurchased and shares of its common stock at a cost of $311,649 or weighted average price of $2.61 and $977,667 or weighted average price of $3.06 per share, respectively.
The Company also granted and restricted stock awards during the three and six months ended June 30, 2023.
2022 Transactions: During the three and six months ended June 30, 2022 the Company issued and shares, respectively, of common stock for vested stock awards and the exercise of stock options and received proceeds of $0 and $0, respectively.
2021 Transactions: DuringThe Company also granted and restricted stock awards during the three and six months ended June 30, 2021 the Company issued and shares, respectively, of common stock for vested stock awards and the exercise of stock options and received proceeds of $9,675 and $120,141, respectively.2022.
| 12 |
The following table sets forth the computation of basic and fully diluted net loss per common share for the three and six months ended June 30, 20222023 and 2021: 2022:
| Schedule of computation of earnings per share | ||||||||||||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||
| Numerator: | ||||||||||||||||||||||||||||||||
| Net loss | $ | (228,034 | ) | $ | (931,967 | ) | $ | (537,429 | ) | $ | (2,555,494 | ) | $ | (104,156 | ) | $ | (228,034 | ) | $ | (264,286 | ) | $ | (537,429 | ) | ||||||||
| Denominator: | ||||||||||||||||||||||||||||||||
| Weighted average common shares: | ||||||||||||||||||||||||||||||||
| Denominator for basic calculation | 51,993,031 | 50,748,437 | 51,906,335 | 50,551,299 | 52,259,002 | 51,993,031 | 52,330,829 | 51,906,335 | ||||||||||||||||||||||||
| Weighted average effects of potentially diluted common stock: | ||||||||||||||||||||||||||||||||
| Stock options (calculated using the treasury method) | 0 | 0 | 0 | 0 | – | – | – | – | ||||||||||||||||||||||||
| Unvested restricted stock grants | 0 | 0 | 0 | 0 | – | – | – | – | ||||||||||||||||||||||||
| Denominator for fully diluted calculation | 51,993,031 | 50,748,437 | 51,906,335 | 50,551,299 | 52,259,002 | 51,993,031 | 52,330,829 | 51,906,335 | ||||||||||||||||||||||||
| Net loss per common share: | ||||||||||||||||||||||||||||||||
| Basic | $ | (0.00 | ) | $ | (0.02 | ) | $ | (0.01 | ) | $ | (0.05 | ) | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.01 | ) | ||||||||
| Fully diluted | $ | (0.00 | ) | $ | (0.02 | ) | $ | (0.01 | ) | $ | (0.05 | ) | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.01 | ) | ||||||||
| Anti-dilutive shares: | ||||||||||||||||||||||||||||||||
| Stock options | 1,815,000 | 1,884,400 | 1,815,000 | 1,884,400 | ||||||||||||||||||||||||||||
| Unvested restricted stock options | 3,652,000 | 1,064,000 | 3,652,000 | 1,064,000 | ||||||||||||||||||||||||||||
DueThe potential common share equivalents are not added to the net lossdenominator for the three and six months ended June 30, 2023 and 2022 because the effect of all potential common share equivalentsinclusion was anti-dilutive, and therefore, all such shares were excluded from the computation of diluted weighted average shares outstanding for both periods. For the three and six months ended June 30, 2022, the amount of potential common share equivalents excluded were for stock options and for unvested restricted stock awards. Due to the net loss for the three and six months ended June 30, 2021, the effect of all potential common share equivalents was anti-dilutive, and therefore, all such shares were excluded from the computation of diluted weighted average shares outstanding for both periods. For the three and six months ended June 30, 2021, the amount of potential common share equivalents excluded were for stock options and for unvested restricted stock awards.
8. COMMITMENTS AND CONTINGENCIES
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
The Company has been named as a defendant in three complaints filed in the United States District Court for the District of Nevada: Yilan Shi v. Paysign, Inc. et. al., filed on March 19, 2020 (“Shi”), Lorna Chase v. Paysign, Inc. et. al., filed on March 25, 2020 (“Chase”), and Smith & Duvall v. Paysign, Inc. et. al., filed on April 2, 2020 (collectively, the “Complaints” or “Securities Class Action”). Smith & Duvall v. Paysign, Inc. et. al. was voluntarily dismissed on May 21, 2020. On May 18, 2020, the Shi plaintiffs and another entity called the Paysign Investor Group each filed a motion to consolidate the remaining Shi and Chase actions and to be appointed lead plaintiff. The Complaints are putative class actions filed on behalf of a class of persons who acquired the Company’s common stock from March 19, 2019 through March 31, 2020, inclusive. The Complaints generally allege that the Company, Mark R. Newcomer, and Mark Attinger violated Section 10(b) of the Securities Exchange Act, of 1934 (the “Exchange Act”), and that Messrs. Newcomer and Attinger violated Section 20(a) of the Exchange Act, by making materially false or misleading statements, or failing to disclose material facts, regarding the Company’s internal control over financial reporting and its financial statements. The Complaints seek class action certification, compensatory damages, and attorney’s fees and costs. On December 2, 2020, the Court consolidated Shi and Chase as In re Paysign, Inc. Securities Litigation and appointed the Paysign Investor Group as lead plaintiff. On January 12, 2021, Plaintiffs filed an Amended Complaint in the consolidated action. Defendants filed a Motion to Dismiss the Amended Complaint on March 15, 2021, which Plaintiffs opposed via an opposition brief filed on April 29, 2021, to which Defendants replied on June 1, 2021. Thus,On February 9, 2023, the motion is now fully briefed. The Court has not set a hearing date on the motion, or informed the parties whether it intendsgranted in part and denied in part Defendants’ Motion to entertain oral argument or rule upon the papers filed.Dismiss. As of the date of this filing, Paysignthe Company cannot give any meaningful estimate of likely outcome or damages.
| 13 |
The Company has also been named as a nominal defendant in two stockholder derivative actions in the United States District Court for the District of Nevada. The first derivative action is entitled Andrzej Toczek, derivatively on behalf of Paysign, Inc. v. Mark R. Newcomer, et al. and was filed on September 17, 2020. This action alleges violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste, largely in connection with the failure to correct information technology controls over financial reporting alleged in the Securities Class Action, thereby causing the Company to face exposure in the Securities Class Action. The complaint also alleges insider trading violations against certain individual defendants. On December 16, 2020, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. The second derivative action is entitled John K. Gray, derivatively on behalf of Paysign, Inc. v. Mark Attinger, et al. and was filed on May 9, 2022. This action involves the same alleged conduct raised in the Toczek action and asserts claims for breach of fiduciary duty in connection with financial reporting, breach of fiduciary duty in connection with alleged insider trading against certain individual defendants, and unjust enrichment. On June 3, 2022, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. On May 10, 2023, the Toczek and Gray actions were consolidated. The Company anticipates filing motions to dismiss given the ruling on the Motion to Dismiss in the consolidated cases. As of the date of this filing, Paysignthe Company cannot give any meaningful estimate of likely outcome or damages.
9. RELATED PARTY
A former member of our Board of Directors who served through December 31, 2022 is also a partner in a law firm that the Company engages for services to review regulatory filings and for various other legal matters. The Company incurred legal expense of $41,019 and $81,753 duringDuring the three and six months ended June 30, 2022, respectively, with the related party law firm. During the three and six months ended June 30, 2021 the Company incurred legal expenseexpenses of $390,17241,019 and $410,88481,753, respectively, with the related party law firm.
10. INCOME TAX PROVISION
The effective tax rate (income tax provision as a percentage of loss before income tax provision) was (126.3%) for the three months ended June 30, 2023, as compared to (13.4%) for the three months ended June 30, 2022, as compared to (0.1%) for the three months ended June 30, 2021.2022. The effective tax rate was (5.729.2%) and (0.15.7%) for the six months ended June 30, 20222023 and 2021,2022, respectively. The effective tax rates vary, primarily as a result of the full valuation on our deferred tax asset in the current year and the tax benefit related to our stock-based compensation expense and a pretax loss in the prior year period.
Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) signed into law in 2020 and the subsequent extension of the CARES Act through September 30, 2021, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company has elected an accounting policy to recognize the government assistance when it is probable that the Company is eligible to receive the assistance and present the credit as a reduction of the related expense. As of June 30, 2023 and December 31, 2022, the Company recorded $836,734 and $1,296,488, respectively in other receivables on the condensed consolidated balance sheet related to U.S. Federal Government refunds.
| 14 |
Item 2. Management’s discussion and analysis of financial condition and results of operations.
Disclosure Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-lookingforward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Forward-Looking Statements”). All statements other than statements of historical fact included in this report are Forward-Looking Statements. These Forward-Looking Statements are based on our current expectations, assumptions, estimates and projections about our business and our industry. Words such as "believe," "anticipate," "expect," "intend," "plan,"“believe,” “anticipate,” “expect,” “intend,” “plan,” “propose,” "may,"“may,” and other similar expressions identify Forward-Looking statements. In the normal course of our business, we, in an effort to help keep our shareholders and the public informed about our operations, may from time-to-time issue certain statements, either in writing or orally, that contain, or may contain, Forward-Looking Statements. Although we believe that the expectations reflected in such Forward-Looking Statements are reasonable, we can give no assurance that such expectations will prove to have been correct. In addition, any statements that refer to expectations, projections, estimates, forecasts, or other characterizations of future events or circumstances are Forward-Looking Statements. These Forward-Looking Statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the Forward-Looking Statements. Such important factors (“Important Factors”) and other factors are disclosed in this report, including those factors discussed in “Part II - Item 1A. Risk Factors.” All prior and subsequent written and oral Forward-Looking Statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the Important Factors described below that could cause actual results to differ materially from our expectations as set forth in any Forward-Looking Statement made by or on behalf of us. You are cautioned not to place undue reliance on these Forward-Looking Statements, which relate only to events as of the date on which the statements are made. We undertake no obligation to publicly revise these Forward-Looking Statements to reflect events or circumstances that arise after the date hereof. You should refer to and carefully review the information in future documents we file with the Securities and Exchange Commission.
Overview
Paysign, Inc. (the “Company,” “Paysign,” “we” or “our”), headquartered in Nevada, was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. Paysign isWe are a vertically integrated provider of prepaid card products and processing services for corporate, consumer and government applications. Our payment solutions are utilized by our corporate customers as a means to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. Public sector organizations can utilize our payment solutions to disburse public benefits or for internal payments. We market our prepaid card solutions under our Paysign® brand. As we are a payment processor and prepaid card program manager, we derive our revenue from all stages of the prepaid card lifecycle.
We operate on a powerful, high-availability payments platform with cutting-edge fintech capabilities that can be seamlessly integrated with our clients’ systems. This distinctive positioning allows us to provide a card processing platform consisting of proprietary systems and software applications based on the unique needs of our clients. We have extended our processing business capabilities through our proprietary Paysign platform. Through the Paysign platform, we provide a variety of services includingend-to-end technologies that securely manage transaction processing, cardholder enrollment, value loading, cardholder account management, reporting,data and analytics, and customer service. The Paysign platform was built on modernOur architecture is known for its cross-platform architecture and designed to be highly flexible, scalable and customizable. The platform’scompatibility, flexibility, and ease of customization has allowed usscalability – allowing our clients and partners to expand our operational capabilities by facilitating our entry into new markets within the payments space. The Paysign platform deliversleverage these advantages for cost benefitssavings and revenue building opportunities to our partners.opportunities.
We have developed prepaid card programsOur suite of product offerings include solutions for corporate incentive and rewards, including, but not limited to,prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, and rewards, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance. We have expanded our product offerings to include additional corporate incentive productsassistance, and demand deposit accounts accessible with a debit card. In the future, we expect to further expand our product offerings into other prepaid card offerings such as payroll cards, travel cards and expense reimbursement cards. Our cards are sponsored by our issuing bank partners.
Our revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income. Revenue from cardholder fees, interchange, card program management fees, and transaction claims processing fees is recorded when the performance obligation is fulfilled. Settlement income is recorded at the expiration of the card program.program and relates solely to our pharma prepaid business which ended in 2022.
| 15 |
We have two categories for our prepaid debit cards: (1) corporate and consumer reloadable cards, and (2) non-reloadable cards.
Reloadable Cards: These types of cards are generally classified as payroll or considered general purpose reloadable (“GPR”) cards. Payroll cards are issued by an employer to an employee in order to allow the employee to access payroll amounts that are deposited into an account linked to their card. GPR cards can also be issued to a consumer at a retail location or mailed to a consumer after completing an on-line application. GPR cards can be reloaded multiple times with a consumer’s payroll, government benefit, a federal or state tax refund or through cash reload networks located at retail locations. Reloadable cards are generally open-loop cards as described below.
Non-Reloadable Cards: These are generally one-time use cards that are only active until the funds initially loaded to the card are spent. These types of cards are generally used as gift or incentive cards. Normally these types of cards are used for the purchase of goods or services at retail locations and cannot be used to receive cash.
Both reloadable and non-reloadable cards may be open-loop, closed-loop, or restricted-loop. Open-loop cards can be used to receive cash at ATM locations by PIN; or purchase goods or services by PIN or signature at retail locations virtually anywhere that the network brand (American Express, Discover, MasterCard,Mastercard, Visa, etc.) is accepted. Closed-loop cards can only be used at a specific merchant. Restricted-loop cards can be used at several merchants, or a defined group of merchants, such as all merchants at a specific shopping mall.
The prepaid card market in the U.S. has experienced significant growth in recent years due to consumers and merchants embracing improved technology, greater convenience, more product choices and greater flexibility. Prepaid cards have also proven to be an attractive alternative to traditional bank accounts for certain segments of the population, particularly those without, or who could not qualify for, a checking or savings account.
We manage all aspects of the prepaid card lifecycle, from managing the card design and approval processes with partners and networks, to production, packaging, distribution, and personalization. We also oversee inventory and security controls, renewals, lost and stolen card management, and replacement. We deploy a 24/7/365 fully staffed, in-house customer service department which utilizes bilingual customer service representatives, Interactive Voice Response, and two-way short message service messaging and text alerts.
Currently, we are focusing our marketing efforts on corporate incentive and expense prepaid card products in various market verticals including but not limited to general corporate expense, healthcare related markets including co-pay assistance,patient affordability solutions, clinical trials and donor compensation, loyalty rewards, and incentive cards.
As part of our continuing platform expansion process, we evaluate current and emerging technologies for applicability to our existing and future software platform. To this end, we engage with various hardware and software vendors in evaluation of various infrastructure components. Where appropriate, we use third-party technology components in the development of our software applications and service offerings. Third-party software may be used for highly specialized business functions, which we may not be able to develop internally within time and budget constraints. Our principal target markets for processing services include prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico.
We have devoted more extensive resources to sales and marketing activities as we have added essential personnel to our marketing, sales and sales team.support teams. We market our Paysign payment solutions through direct marketing by the Company’s sales team. Our primary market focus is on companies and municipalities that require a streamlined payment solution for rewards, rebates, payment assistance, and other payments to their customers, employees, agents and others. To reach these markets, we focus our sales efforts on direct contact with our target market and attendance at various industry specific conferences. We may, at times, utilize independent contractors who make direct sales and are paid on a commission basis only.commissions and/or restricted stock awards. We market our Paysign Premier product through existing communication channels to a targeted segment of our existing cardholders, as well as to a broad group of individuals, ranging from non-banked to fully banked consumers with a focus on long term users of our product.
| 16 |
In 2022,For the remainder of 2023, we plan to continue to invest additional funds in technology improvements, sales and marketing, fraud and disputes, customer service, and regulatory compliance. From time to time, we evaluate raising capital to enable us to diversify into new market verticals. If we do not raise new capital, we believe that we will still be able to support our existing business and expand into new vertical markets using internally generated funds.
The coronavirus (“COVID-19”) pandemic, which started in late 2019 and reached the United States in early 2020, continues to significantly impact the economy of the United States and the rest of the world. While the direct disruption appears to have significantly mitigated due to the availability of vaccines and other factors, the ultimate duration and severity of the pandemic remain uncertain, particularly given the development of new variants that continue to spread, and the economic repercussions are still manifesting themselves. The COVID-19 outbreak caused plasma center closures, and the stimulus packages signed into law during 2020 and 2021 reduced the incentive for individuals to donate plasma for supplementary income. Additionally, labor shortages at plasma donation centers and restrictions preventing Mexican nationals with tourist visas from being compensated for donating plasma, have further impacted donations. Those developments have had, and are expected to continue to have, an adverse impact on the Company’s results of operations. Offsetting those headwinds, inflationary pressures for food, gasoline, and other products and services appear to be driving individuals back into the plasma donation centers based upon the increase we experienced in the number of loads per average donation center in the second quarter of 2022 versus the first quarter of 2022. While we remain cautiously optimistic and have seen improvements in our operating results on an aggregated basis, we cannot foresee how long it may take the Company to attain pre-pandemic operating levels on a per plasma donation center basis. Given the uncertainty around the extent and timing of the potential future spread or mitigation of COVID-19 and variants and around the imposition or relaxation of protective measures, management cannot at this time estimate with reasonable accuracy COVID-19’s further impact on the Company’s results of operations, cash flows or financial condition.
Results of Operations
Comparison of the Three Months Ended June 30, 2023 to the Three Months Ended June 30, 2022 and 2021
The following table summarizes our consolidated financial results:results for the three months ended June 30, 2023 in comparison to the three months ended June 30, 2022:
Three Months Ended June 30, (unaudited) | Variance | Three Months Ended June 30, (Unaudited) | Variance | |||||||||||||||||||||||||||||
| 2022 | 2021 | $ | % | 2023 | 2022 | $ | % | |||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||||||
| Plasma industry | $ | 7,806,201 | $ | 5,947,313 | $ | 1,858,888 | 31.3% | $ | 10,014,461 | $ | 7,806,201 | $ | 2,208,260 | 28.3% | ||||||||||||||||||
| Pharma industry | 773,311 | 641,037 | 132,274 | 20.6% | 729,236 | 773,311 | (44,075 | ) | (5.7% | ) | ||||||||||||||||||||||
| Other | 19,264 | 62,940 | (43,676 | ) | (69.4% | ) | 297,354 | 19,264 | 278,090 | 1443.6% | ||||||||||||||||||||||
| Total revenues | 8,598,776 | 6,651,290 | 1,947,486 | 29.3% | 11,041,051 | 8,598,776 | 2,442,275 | 28.4% | ||||||||||||||||||||||||
| Cost of revenues | 3,900,965 | 3,498,723 | 402,242 | 11.5% | 5,425,311 | 3,900,965 | 1,524,346 | 39.1% | ||||||||||||||||||||||||
| Gross profit | 4,697,811 | 3,152,567 | 1,545,244 | 49.0% | 5,615,740 | 4,697,811 | 917,929 | 19.5% | ||||||||||||||||||||||||
| Gross margin % | 54.6% | 47.4% | 50.9% | 54.6% | ||||||||||||||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||||||||||
| Selling, general and administrative | 4,255,976 | 3,474,562 | 781,414 | 22.5% | 5,304,625 | 4,255,976 | 1,048,649 | 24.6% | ||||||||||||||||||||||||
| Depreciation and amortization | 713,180 | 614,182 | 98,998 | 16,1% | 958,001 | 713,180 | 244,821 | 34.3% | ||||||||||||||||||||||||
| Total operating expenses | 4,969,156 | 4,088,744 | 880,412 | 21.5% | 6,262,626 | 4,969,156 | 1,293,470 | 26.0% | ||||||||||||||||||||||||
| Loss from operations | $ | (271,345 | ) | $ | (936,177 | ) | $ | 664,832 | (71.0% | ) | $ | (646,886 | ) | $ | (271,345 | ) | $ | (375,541 | ) | 138.4% | ||||||||||||
| Net loss | $ | (228,034 | ) | $ | (931,967 | ) | $ | 703,933 | (75.5% | ) | $ | (104,156 | ) | $ | (228,034 | ) | $ | 123,878 | (54.3% | ) | ||||||||||||
| Net margin % | (2.7% | ) | (14.0% | ) | (0.9% | ) | (2.7% | ) | ||||||||||||||||||||||||
The increase in total revenues of $2,442,275 for the three months ended June 30, 2023 compared to the same period in the prior year consisted primarily of a $2,208,260 increase in Plasma revenue, a $44,075 decrease in Pharma revenue, and a $278,090 increase in Other revenue. The increase in Plasma revenue was primarily due to an increase in the number of plasma centers and donations, and, consequently, dollars loaded to cards, cardholder fees, and interchange, as there continues to be an increase in demand for plasma driven by global increases of plasma protein therapies. The decrease in Pharma revenue was primarily due to the end of our pharma prepaid programs in 2022, offset by the launch of new pharma patient affordability programs. The increase in Other revenue was primarily due to the launch of new payroll, retail programs, and other prepaid card disbursement programs.
| 17 |
The increase in total
Cost of revenues of $1,947,486 for the three months ended June 30, 2023 increased $1,524,346 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, and sales and commission expense. Cost of revenues increased during the second quarter of 2023 primarily due to an increase in cardholder usage activity and associated network expenses such as interchange and ATM costs, an increase in plastics and collateral related to an increase in the number of unique card loads, an increase in network expenses and sales commissions related to the growth in our pharma patient affordability business, a new direct network connection with Mastercard, and an increase in customer service expenses associated with wage inflation pressures and the overall growth in our business, offset by a decline in postage.
Gross profit for the three months ended June 30, 2023 increased $917,929 compared to the same period in the prior year resulting primarily from the increase in Plasma revenue and the beneficial impact of a variable cost structure as many of the plasma transaction costs are variable in nature which are provided by third parties who charge us based on the number of active cards outstanding and the number of transactions that occurred during the period. The increase in gross profit was offset by the termination of our pharma prepaid business in 2022, price increases by many of our third party service providers, a new direct network connection with Mastercard, and an increase in customer service expenses mentioned above. The decrease in gross margin resulted from the aforementioned factors.
Selling, general and administrative expenses (“SG&A”) for the three months ended June 30, 2023 increased $1,048,649 compared to the same period in the prior year and consisted primarily of an increase in compensation and benefits of approximately $690,000 due to continued hiring to support the Company’s growth, a tight labor market and increased personnel insurance costs, an increase in stock based compensation expense of approximately $340,000, and an increase in non-IT outside professional services of approximately $235,000. This increase was offset by a $210,000 increase in the amount of capitalized platform development costs and a decrease in all other operating expenses of approximately $8,000.
Depreciation and amortization expense for the three months ended June 30, 2023 increased $244,821 compared to the same period in the prior year. The increase in depreciation and amortization expense was primarily due to continued capitalization of new software development costs and equipment purchases related to the continued enhancements to our processing platform.
For the three months ended June 30, 2023, we recorded a loss from operations of $646,886 representing a decline of $375,541 compared to a loss from operations of $271,345 during the same period last year related to the aforementioned factors.
Other income for the three months ended June 30, 2023, increased $530,640 primarily related to an increase in interest rates and the associated interest income received on higher bank account balances at our sponsor bank.
We recorded an income tax expense of $58,137 for the three months ended June 30, 2023, which equates to an effective tax rate of (126.3%) primarily as a result of state taxes, the full valuation on our deferred tax asset, the tax benefit related to our stock-based compensation expense and the pretax loss during the period. We recorded an income tax expense of $26,916 for the three months ended June 30, 2022, which equates to an effective tax rate of (13.4%) primarily as a result of the full valuation on our deferred tax asset, the tax benefit related to our stock-based compensation expense and the pretax loss during the period.
The net loss for the three months ended June 30, 2023 was $104,156, an improvement of $123,878 compared to the net loss of $228,034 for the three months ended June 30, 2022. The overall change in net loss relates to the aforementioned factors.
| 18 |
Comparison of the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022
The following table summarizes our consolidated financial results for the six months ended June 30, 2023 in comparison to the six months ended June 30, 2022:
Six Months Ended June 30, (unaudited) | Variance | |||||||||||||||
| 2023 | 2022 | $ | % | |||||||||||||
| Revenues | ||||||||||||||||
| Plasma industry | $ | 19,374,528 | $ | 15,200,565 | $ | 4,173,963 | 27.5% | |||||||||
| Pharma industry | 1,318,798 | 1,579,879 | (261,081 | ) | (16.5% | ) | ||||||||||
| Other | 491,015 | 38,971 | 452,044 | 1159.9% | ||||||||||||
| Total revenues | 21,184,341 | 16,819,415 | 4,364,926 | 26.0% | ||||||||||||
| Cost of revenues | 10,520,932 | 7,123,355 | 3,397,577 | 47.7% | ||||||||||||
| Gross profit | 10,663,409 | 9,696,060 | 967,349 | 10.0% | ||||||||||||
| Gross margin % | 50.3% | 57.6% | ||||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 10,250,075 | 8,896,888 | 1,353,187 | 15.2% | ||||||||||||
| Depreciation and amortization | 1,803,017 | 1,392,351 | 410,666 | 29.5% | ||||||||||||
| Total operating expenses | 12,053,092 | 10,289,239 | 1,763,853 | 17.1% | ||||||||||||
| Loss from operations | $ | (1,389,683 | ) | $ | (593,179 | ) | $ | (796,504 | ) | 134.3% | ||||||
| Net loss | $ | (264,286 | ) | $ | (537,429 | ) | $ | 273,143 | (50.8% | ) | ||||||
| Net margin % | (1.2% | ) | (3.2% | ) | ||||||||||||
The increase in total revenues of $4,364,926 for the six months ended June 30, 2023 compared to the same period in the prior year consisted primarily of a $1,858,888$4,173,963 increase in Plasma revenue and a $132,274$452,044 increase in PharmaOther revenue, offset by a $43,676$261,081 decrease in OtherPharma revenue. The increase in Plasma revenue was primarily due to an increase in the number of plasma centers and donations, and, consequently, dollars loaded to cards, cardholder fees, and interchange, as COVID-19 restrictions such as donation center closures, mobility restrictions and Federal government stimulus measures were relaxed compared to the prior year period. The increase in Pharma revenue was primarily due to the launch of new Pharma copay programs offset by the end of a number of Pharma prepaid programs. The decrease in Other revenue was primarily due to the recognition of settlement income from a rewards program that terminated in the second quarter of 2021.
Cost of revenues for the three months ended June 30, 2022 increased $402,242 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivitydriven by our new payroll, retail, and data center expenses, network fees, bank fees,other prepaid card production and postage costs, customer service, program management, application integration setup, and sales and commission expense. Cost of revenues increased during the second quarter of 2022 primarily due to the increase in cardholder usage activity, the increase in plastics, collateral and postage related to upfront costs associated with new openings and competitive conversion of 62 plasma donation centers, the increase in network expenses related to our Pharma copay business, and the increase in customer service expenses, offset by a decline in sales commissions related to the restructuring of an agreement in the first quarter of 2022.
Gross profit for the three months ended June 30, 2022 increased $1,545,244 compared to the same period in the prior year resulting from the increase in Plasma revenue, the restructuring of an agreement mentioned above, and the beneficial impact of a variable cost structure as many of the Plasma transaction costs are variable in nature which are provided by third parties who charge us based on the number of transactions that occurred during the period.disbursement programs. The increase in gross profit was offset by the upfront costs associated with the 62 new plasma donation centers that were added during the quarter and the increase in customer service expenses relating to the overall growth of our business. The increase in gross margin resulted from the aforementioned factors.
Selling, general and administrative expenses (“SG&A”) for the three months ended June 30, 2022 increased $781,414 or 22.5% compared to the same period in the prior year and consisted primarily of an increase in compensation and benefits of $890,000, a decrease in stock-based compensation of $52,600, a decrease in outside professional services for legal, tax, accounting and consultants of $151,400, a decrease in insurance of $15,000, an increase in technologies and telecom of $237,000, a decrease in rent, utilities, and maintenance of $14,100, an increase in travel and entertainment of $57,200, and an increase in other operating expenses of $210,000. The remainder of the difference is primarily related to an increase in capitalized software development costs.
Depreciation and amortization expense for the three months ended June 30, 2022 increased $98,998 compared to the same period in the prior year. The increase in depreciation and amortization expense was primarily due to continued capitalization of new software and equipment, and continued enhancements to our platform.
For the three months ended June 30, 2022 we recorded a loss from operations of $271,345 representing a net increase of $664,832 compared to the same period last year related to the aforementioned factors.
Other income for the three months ended June 30, 2022 increased $65,217 related to an increase in interest rates and the associated interest income received on higher bank account balances at our sponsor bank and lower interest expense related to the financing of insurance premiums.
We recorded an income tax expense of $26,916 for the three months ended June 30, 2022, which equates to an effective tax rate of (13.4%) primarily as a result of the full valuation on our deferred tax asset in both the current and prior period and the tax benefit related to our stock-based compensation and a pretax loss in the prior period. We recorded an income tax expense of $800 for the three months ended June 30, 2021 due to estimated state tax payments.
The net loss for the three months ended June 30, 2022 was $228,034, an improvement of $703,933 compared to the net loss of $931,967 for the three months ended June 30, 2021. The overall change in net loss relates to the aforementioned factors.
Six Months Ended June 30, 2022 and 2021
The following table summarizes our consolidated financial results:
Six Months Ended June 30, (unaudited) | Variance | |||||||||||||||
| 2022 | 2021 | $ | % | |||||||||||||
| Revenues | ||||||||||||||||
| Plasma industry | $ | 15,200,565 | $ | 11,330,464 | $ | 3,870,101 | 34.2% | |||||||||
| Pharma industry | 1,579,879 | 1,523,867 | 56,012 | 3.7% | ||||||||||||
| Other | 38,971 | 76,387 | (37,416 | ) | (49.0% | ) | ||||||||||
| Total revenues | 16,819,415 | 12,930,718 | 3,888,697 | 30.1% | ||||||||||||
| Cost of revenues | 7,123,355 | 6,946,345 | 177,010 | 2.5% | ||||||||||||
| Gross profit | 9,696,060 | 5,984,373 | 3,711,687 | 62.0% | ||||||||||||
| Gross margin % | 57.6% | 46.3% | ||||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 8,896,888 | 7,339,548 | 1,557,340 | 21.2% | ||||||||||||
| Depreciation and amortization | 1,392,351 | 1,210,030 | 182,321 | 15.1% | ||||||||||||
| Total operating expenses | 10,289,239 | 8,549,578 | 1,739,661 | 20.3% | ||||||||||||
| Loss from operations | $ | (593,179 | ) | $ | (2,565,205 | ) | $ | 1,972,026 | (76.9% | ) | ||||||
| Net loss | $ | (537,429 | ) | $ | (2,555,494 | ) | $ | 2,018,065 | (79.0% | ) | ||||||
| Net margin % | (3.2% | ) | (19.8% | ) | ||||||||||||
The increase in total revenues of $3,888,697 for the six months ended June 30, 2022 compared to the same period in the prior year consisted primarily of a $3,870,101 increase in Plasma revenue and a $56,012 increase in Pharma revenue, offset by a $37,416 decrease in Other revenue. The increase in Plasma revenue was primarily due to an increase in the number of plasma centers and donations, and, consequently, dollars loaded to cards, cardholder fees, and interchange, as COVID-19 restrictions such as donation center closures, mobility restrictions and Federal government stimulus measures were relaxed compared to the prior year period. The increase in Pharma revenue was primarily due to the end of our pharma prepaid programs in 2022, offset by the launch of new Pharma copay programs offset by the end of a number of Pharma prepaidpharma patient affordability programs. The decrease in Other revenue was primarily driven by the recognition of settlement income from a rewards program that ended during the second quarter of 2021.
Cost of revenues for the six months ended June 30, 20222023 increased $177,010$3,397,577 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, and sales and commission expense. Cost of revenues increased during the six months of 20222023 primarily due to the increase in cardholder usage activity theand associated network expenses such as interchange and ATM costs, an increase in plastics, collateral and postage expenses related to upfront costs associated with the de novo opening or competitive conversion of 71 plasma donation centers that we service,changes to collateral materials, the increase in network expenses related to our Pharma copaypharma patient affordability business, and the increase in customer service expenses associated with wage inflation pressures and the overall growth in our business, offset by a decline in sales commissions related to the restructuring of an agreement in the first quarter of 2022.
| 19 |
Gross profit for the six months ended June 30, 20222023 increased $3,711,687$967,349 compared to the same period in the prior year resulting from the increase in Plasma revenue, the restructuring of an agreement mentioned above, and the beneficial impact of a variable cost structure as many of the Plasmaplasma transaction costs are provided by third parties who charge us based on the number of transactions that occurred during the period, with a lower per-transaction cost at larger numbers of transactions.period. The increase in Grossgross profit was offset by the upfront costs associatedtermination of our pharma prepaid business in 2022, price increases by many of our third party service providers, a new direct network connection with the 71 new plasma donation centers that were added during the six month periodMastercard, and thean increase in customer service expenses relating to the overall growth of our business.mentioned above. The increasedecrease in gross margin resulted from the aforementioned factors.
SG&A for the six months ended June 30, 20222023 increased $1,557,340 or 21.2%$1,353,187 compared to the same period in the prior year and consisted primarily of an increase in compensation and benefits of $1,294,200,approximately $1,688,000 due to continued hiring to support the Company’s growth, a decreasetight labor market and increased personnel insurance costs, an increase in stock-basedstock based compensation expense of $119,300, a decreaseapproximately $391,000, an increase in outside professional services for legal, tax, accounting and consultantsnon-IT outside professional services of $245,800, an increase in legal settlements of $354,000, an increase in insurance of $95,800, an increase in technologies and telecom of $415,100, a decrease in rent, utilities, and maintenance of $43,900, an increase in travel and entertainment of $131,800,approximately $117,000, and an increase in all other operating expenses of $375,100. The remainder of the difference is primarily related toapproximately $13,000. This increase was offset by an increase of approximately $856,000 in capitalized softwareplatform development costs.
Depreciation and amortization expense for the six months ended June 30, 20222023 increased $182,300$410,666 compared to the same period in the prior year. The increase in depreciation and amortization expense was primarily due to continued capitalization of new softwaredevelopment costs and equipment andpurchases related to the continued enhancements to our processing platform.
For the six months ended June 30, 20222023 we recorded a loss from operations of $593,179$1,389,683 representing a net increasedecline of $1,972,026$796,504 compared to the same period last year related to the aforementioned factors.
Other income for the six months ended June 30, 20222023 increased $72,452$1,100,501 related to an increase in interest rates and the associated interest income received on higher bank account balances at our sponsor bank and lower interestbank.
We recorded an income tax expense of $59,667 for the six months ended June 30, 2023 which equates to an effective tax rate of (29.2%) primarily as a result of the full valuation on our deferred tax asset, the tax benefit related to our stock-based compensation expense and the financing of insurance premiums.
pretax loss during the period. We recorded an income tax expense of $28,813 for the six months ended June 30, 2022, which equates to an effective tax rate of (5.7%) percent primarily as a result of the full valuation on our deferred tax asset, in both the current and prior period and the tax benefit related to our stock-based compensation expense and athe pretax loss induring the prior period.We recorded an income tax expense of $2,400 for the six months ended June 30, 2021 due to estimated state tax payments.
The net loss for the six months ended June 30, 20222023 was $537,429,$264,286, an improvement of $2,018,065$273,143 compared to the net loss of $2,555,494$537,429 for the six months ended June 30, 2021.2022. The overall change in net loss relates to the aforementioned factors.
Key Performance Indicators and Non-GAAP Measures
Management reviews a number of metrics to help us monitor the performance of and identify trends affecting our business. We believe the following measures are the primary indicators of our quarterly and annual revenues:
Gross Dollar Volume Loaded on Cards – Represents the total dollar volume of funds loaded to all of our prepaid card programs. Our gross dollar volume loaded on cards was $376$405 million and $267$375 million for the three months ended June 30, 20222023 and 2021, respectively. That gross dollar volume was $699 million and $546 million for the six months ended June 30, 2022, and 2021, respectively. We use this metric to analyze the total amount of money moving into our prepaid card programs.
| 20 |
Conversion Rates on Gross Dollar Volume Loaded on Cards – Equals revenues, gross profit or net incomeloss conversion rates of gross dollar volume loaded on cards which are calculated by taking our total revenues, gross profit or net income (loss),loss, respectively, as a numerator and dividing by the gross dollar volume loaded on cards as a denominator. As we derive a number of our financial results from cardholder fees, we utilize these metrics as an indication of the amount of money that is added to cards and will eventually be converted to revenues, gross profit and net income.income (loss). Our total revenue conversion rates for the three months ended June 30, 2023 and 2022 and 2021 were 2.29%2.73% or 229273 basis points (“bps”), and 2.49%2.29% or 249229 bps, respectively, of gross dollar volume loaded on cards. Our total gross profit conversion rates for the three months ended June 30, 2023 and 2022 were 1.39% or 139 bps, and 2021 were 1.25% or 125 bps, and 1.18% or 118 bps, respectively, of gross dollar volume loaded on cards. Our net incomeloss conversion rates for the three months ended June 30, 2023 and 2022 were (0.01%) or (1) bp, and 2021 were (0.06)%(0.06%) or (6) bps, and (0.35)% or (35) bps, respectively, of gross dollar volume loaded on cards. Our total revenue conversion rates for the six months ended June 30, 2022 and 2021 were 2.41% or 241 bps, and 2.37% or 237 bps, respectively, of gross dollar volume loaded on cards. Our total gross profit conversion rates for the six months ended June 30, 2022 and 2021 were 1.39% or 139 bps, and 1.10% or 110 bps, respectively, of gross dollar volume loaded on cards. Our net income conversion rates for the six months ended June 30, 2022 and 2021 were (0.08)% or (8) bps, and (0.47)% or (47) bps, respectively, of gross dollar volume loaded on cards.
Management also reviews key performance indicators, such as revenues, gross profit, operational expenses as a percent of revenues, and cardholder participation. In addition, we consider certain non-GAAP (or "adjusted"“adjusted”) measures to be useful to management and investors evaluating our operating performance for the periods presented, and provide a financial tool for evaluating our ongoing operations, liquidity and management of assets. This information can assist investors in assessing our financial performance and measures our ability to generate capital for deployment and investment in new card programs. These adjusted metrics are consistent with how management views our business and are used to make financial, operating and planning decisions. These metrics, however, are not measures of financial performance under GAAP and should not be considered a substitute for revenue, operating income, net income (loss), earnings (loss) per share (basic and diluted) or net cash from operating activities as determined in accordance with GAAP. We consider the following non-GAAP measures, which may not be comparable to similarly titled measures reported by other companies, to be key performance indicators:
“EBITDA” is defined as earnings before interest, income taxes, and depreciation and amortization expense and "Adjusted EBITDA"“Adjusted EBITDA” reflects the adjustment to EBITDA to exclude stock-based compensation expense. A reconciliation of net loss to Adjusted EBITDA is provided in the table below.
| Three Months Ended June 30, | Six Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||
| Reconciliation of Adjusted EBITDA to net loss: | ||||||||||||||||||||||||||||||||
| Net loss | $ | (228,034 | ) | $ | (931,967 | ) | $ | (537,429 | ) | $ | (2,555,494 | ) | $ | (104,156 | ) | $ | (228,034 | ) | $ | (264,286 | ) | $ | (537,429 | ) | ||||||||
| Income tax provision | 26,916 | 800 | 28,813 | 2,400 | 58,137 | 26,916 | 59,667 | 28,813 | ||||||||||||||||||||||||
| Interest income | (70,227 | ) | (5,010 | ) | (84,563 | ) | (12,111 | ) | ||||||||||||||||||||||||
| Interest income, net | (600,867 | ) | (70,227 | ) | (1,185,064 | ) | (84,563 | ) | ||||||||||||||||||||||||
| Depreciation and amortization | 713,180 | 614,182 | 1,392,351 | 1,210,030 | 958,001 | 713,180 | 1,803,017 | 1,392,351 | ||||||||||||||||||||||||
| EBITDA | 441,835 | (321,995 | ) | 799,172 | (1,355,175 | ) | 311,115 | 441,835 | 413,334 | 799,172 | ||||||||||||||||||||||
| Stock-based compensation | 488,287 | 540,921 | 1,057,789 | 1,177,135 | 830,426 | 488,287 | 1,448,670 | 1,057,789 | ||||||||||||||||||||||||
| Adjusted EBITDA | $ | 930,122 | $ | 218,926 | $ | 1,856,961 | $ | (178,040 | ) | $ | 1,141,541 | $ | 930,122 | $ | 1,862,004 | $ | 1,856,961 | |||||||||||||||
Liquidity and Capital Resources
The following table sets forth the major sources and uses of cash:
Six Months Ended June 30, (unaudited) | Six Months Ended June 30, (Unaudited) | |||||||||||||||
| 2022 | 2021 | 2023 | 2022 | |||||||||||||
| Net cash provided by operating activities | $ | 16,399,465 | $ | 17,581,753 | $ | 151,348 | $ | 16,399,465 | ||||||||
| Net cash used in investing activities | (1,575,209 | ) | (1,261,556 | ) | (3,044,110 | ) | (1,575,209 | ) | ||||||||
| Net cash provided by financing activities | – | 120,141 | ||||||||||||||
| Net cash used in financing activities | (968,067 | ) | – | |||||||||||||
| Net increase in cash and restricted cash | $ | 14,824,256 | $ | 16,440,338 | $ | (3,860,829 | ) | $ | 14,824,256 | |||||||
| 21 |
Comparison of Six Monthsmonths Ended June 30, 20222023 and 20212022
During the six months ended June 30, 20222023 and 2021,2022, we financed our operations through internally generated funds.
Cash provided by operating activities decreased $1,182,288$16,248,117 for the six months ended June 30, 2022,2023, as compared to the same period in the prior year. The decrease is primarily due to changes in cash flows from operating assets and liabilities, particularly decreases in cash flows from other receivablescustomer card funding of $420,033$17,507,204 related to timing of customer deposits for plasma and pharma programs and an increase in accounts receivable of $2,973,641. These cash flow decreases were partially offset by cash flow increases of $621,264 primarily related to the collection of employee retention credits recorded in the current year, increase in accounts payable and accrued liabilities of $891,940 associated with the timing of a payment due to a third-party service provider, and customer card funding of $1,970,675 primarily related to the return of restricted cash associated with the end of a number of Pharma prepaid programs. These decreases were partially offset by$2,621,446, an improvement in net loss from operations of $2,018,065, a decrease$273,143, an increase in cash flows from stock-based compensation of $119,346$390,881, and an increase in cash flows from depreciation and amortization of $182,321.$410,666. The changes in accounts receivable and accounts payable are primarily related to the growth in our pharma patient affordability business as we are invoiced by third party service providers at the end of the period and are due monies from our pharma patient affordability customers to cover these amounts due at the end of the period.
Cash used in investing activities increased $313,653$1,468,901 for the six months ended June 30, 20222023 as compared to the six months ended June 30, 2021.same period in the prior year. The change between periods was primarily attributed to an increase in the capitalization of internally developed software as we continue to invest in our technology platform.
Cash provided byused in financing activities was zeroincreased $968,067 for the six months ended June 30, 20222023 as compared to cash provided by financing activities of $120,141 for the six months ended June 30, 2021. Cash provided by financing activitiessame period in the 2021 period consistedprior year. The change between periods was attributed to the repurchase of 319,558 shares of the company’s common stock at a weighted average price of $3.06 per share.
Our significant contractual cash received fromrequirements also include ongoing payments for lease liabilities. For additional information regarding our cash commitments and contractual obligations, see "Note 4 – LEASE” in the exercise of employee stock options totaling $120,141.notes to the accompanying consolidated financial statements.
Sources of Liquidity
We believe that our available cash on hand, excluding restricted cash, at June 30, 20222023 of $6,527,476,$7,670,677, along with our forecast for revenues and cash flows for the remainder of the year2023 and for 2023,2024, will be sufficient to sustain our operations for the next twelveeighteen months.
Off-Balance Sheet Arrangements
We do In light of the recent bank failures, we continue to monitor the health and soundness of our bank relationships through publicly available information. Based on recent SEC filings, we have not havediscovered any off-balance sheet arrangementsissues that are reasonably likelywould cause us to have a current or future effect onalter our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.relationships.
Critical Accounting Policies and Estimates
Our significant accounting policies are described in Note 12 of the Notes to Consolidated Financial Statements andof our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.2022.
The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Our estimates are based on our experience and our interpretation of economic, political, regulatory, and other factors that affect our business prospects. Actual results may differ significantly from our estimates.
| 22 |
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
Because we are a smaller reporting company, we are not required to provide the information called for by this Item.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures.
Disclosure controls and procedures means controls and other procedures that are designed to ensure that the information we are required to disclose in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and to ensure that information required to be disclosed by us in those reports is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934)Act) as of June 30, 2022.2023. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of June 30, 2022,2023, the end of the period covered by this Quarterly Report on Form 10-Q.
Changes in Internal Control over Financial Reporting
During the quarter ended June 30, 2022,2023, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 23 |
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
The Company has been named as a defendant in three complaints filed in the United States District Court for the District of Nevada: Yilan Shi v. Paysign, Inc. et. al., filed on March 19, 2020 (“Shi”), Lorna Chase v. Paysign, Inc. et. al., filed on March 25, 2020 (“Chase”), and Smith & Duvall v. Paysign, Inc. et. al., filed on April 2, 2020 (collectively, the “Complaints” or “Securities Class Action”). Smith & Duvall v. Paysign, Inc. et. al. was voluntarily dismissed on May 21, 2020. On May 18, 2020, the Shi plaintiffs and another entity called the Paysign Investor Group each filed a motion to consolidate the remaining Shi and Chase actions and to be appointed lead plaintiff. The Complaints are putative class actions filed on behalf of a class of persons who acquired the Company’s common stock from March 19, 2019 through March 31, 2020, inclusive. The Complaints generally allege that the Company, Mark R. Newcomer, and Mark Attinger violated Section 10(b) of the Exchange Act, and that Messrs. Newcomer and Attinger violated Section 20(a) of the Exchange Act, by making materially false or misleading statements, or failing to disclose material facts, regarding the Company’s internal control over financial reporting and its financial statements. The Complaints seek class action certification, compensatory damages, and attorney’s fees and costs. On December 2, 2020, the Court consolidated Shi and Chase as In re Paysign, Inc. Securities Litigation and appointed the Paysign Investor Group as lead plaintiff. On January 12, 2021, Plaintiffs filed an Amended Complaint in the consolidated action. Defendants filed a Motion to Dismiss the Amended Complaint on March 15, 2021, which Plaintiffs opposed via an opposition brief filed on April 29, 2021, to which Defendants replied on June 1, 2021. Thus,On February 9, 2023, the motion is now fully briefed. The Court has not set a hearinggranted in part and denied in part Defendants’ Motion to Dismiss. As of the date onof this filing, the motion,Company cannot give any meaningful estimate of likely outcome or informed the parties whether it intends to entertain oral argument or rule upon the papers filed.damages.
The Company has also been named as a nominal defendant in two stockholder derivative actions in the United States District Court for the District of Nevada. The first derivative action is entitled Andrzej Toczek, derivatively on behalf of Paysign, Inc. v. Mark R. Newcomer, et al. and was filed on September 17, 2020. This action alleges violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste, largely in connection with the failure to correct information technology controls over financial reporting alleged in the Securities Class Action, thereby causing the Company to face exposure in the Securities Class Action. The complaint also alleges insider trading violations against certain individual defendants. On December 16, 2020, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. The second derivative action is entitled John K. Gray, derivatively on behalf of Paysign, Inc. v. Mark Attinger, et al. and was filed on May 9, 2022. This action involves the same alleged conduct raised in the Toczek action and asserts claims for breach of fiduciary duty in connection with financial reporting, breach of fiduciary duty in connection with alleged insider trading against certain individual defendants, and unjust enrichment. On June 3, 2022, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. On May 10, 2023, the Toczek and Gray actions were consolidated. The Company anticipates filing motions to dismiss given the ruling on the Motion to Dismiss in the consolidated cases. As of the date of this filing, the Company cannot give any meaningful estimate of likely outcome or damages.
Item 1A. Risk Factors.
Because we are a smaller reporting company, we are not required to provide the information called for by this Item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Purchases of Equity Securities
During the quarter ended June 30, 2022,2023, we issued, pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, a total of 105,00074,000 shares of common stock for restricted stock awards previously earned and vested to certain directors, consultants and employees.employees and the exercise of stock options.
| 24 |
The following table sets forth certain information relating to the purchases of our common stock by us and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) under the Exchange Act during the three months ended June 30, 2023.
| Period | Total Number of Shares Purchased | Weighted Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) | Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs | ||||||||||||
| April 1, 2023 - April 30, 2023 | – | $ | – | – | $ | 4,333,982 | ||||||||||
| May 1, 2023 - May 31, 2023 | 23,058 | 2.69 | 23,058 | 4,272,167 | ||||||||||||
| June 1, 2023 - June 30, 2023 | 96,500 | 2.59 | 96,500 | 4,022,982 | ||||||||||||
| Total | 119,558 | $ | 2.61 | 119,558 | $ | 4,022,982 | ||||||||||
____________________
(1) On March 21, 2023, our board of directors authorized a stock repurchase program to repurchase up to $5 million of our common stock, subject to certain conditions, in the open market, in privately negotiated transactions, or by other means in compliance with Rule 10b-18 under the Exchange Act. The program is expected to be completed within 36 months from the commencement date.
Item 5. Other Information
During the quarter ended June 30, 2023, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).
Item 6. Exhibits.
| Paysign, Inc. 2023 Equity Incentive Plan (1) | |
| 31.1* | Rule 13a-14(a)/15d-14(a) Certifications |
| Rule 13a-14(a)/15d-14(a) Certifications | |
| Section 1350 Certifications | |
| Section 1350 Certifications | |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). |
______________
* Filed herewith.
(1) Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 9, 2023 (File Number 001-38623).
| 25 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PAYSIGN, INC. | |
| Date: August | /s/ Mark Newcomer |
By: Mark Newcomer, Chief Executive Officer (principal executive officer) | |
| Date: August | /s/ Jeff Baker |
By: Jeff Baker, Chief Financial Officer (principal financial and accounting officer) |
| 26 |